Proper bone development requires the coordinated and calibrated action of various cells, hormones, enzymes and nutrients. In this paper, we present two clinical cases of metabolic bone disorders – one with excessive fibroblast growth factor-23 (FGF23) and the other, with low alkaline phosphatase. FGF23 and alkaline phosphatase are not-so-well-known players in bone health. This paper puts the spotlight on these two, and discusses their role in bone development, and how abnormal levels lead to disease.
No takes yet. Share an insight, caveat, or question.
Sandoval et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: